The demand within the global acute lymphoblastic leukaemia market is poised to rise in the years to come by. The relevance of studying and understanding the nature of cancers has given an impetus to market growth. The incidence of various types of cancers has increased by a dramatic chase in recent times, and this has raised concerns across the medical and healthcare industries. The domain of oncology is focusing on developing core technologies and diagnostic facilities to manage cancers in ailing individuals. Furthermore, there have been several attempts to develop medications that can fight against cancer cells. The aforementioned trends are suggestive of the seriousness of the healthcare and medical industries to deal with various types of cancers. Acute lymphoblastic leukaemia is one such cancer has been the cause of several deaths in the past. Henceforth, researchers are actively looking at finding antigens to destroy this cancer in the body.

acute lymphoblastic leukemia market

In this report preview by Transparency Market Research (TMR), the leading factors responsible for the growth of the global acute lymphoblastic leukaemia market have been enunciated. The survival rate of older patients suffering from leukaemia is lower as against young patients. This is an important consideration for research labs looking at studying the survival rates of patients with acute lymphoblastic leukaemia. Several countries have developed dedicated research facilities for cancer research, and each of these facilities are equipped with state-of-the-art equipment and technologies. Besides, countries in the western world approve heavy annual budgets for medical research. A large part of this budget is allocated for cancer research and development. The global acute lymphoblastic leukaemia market could fetch formidable revenues from the budget allocated by nations in healthcare and medical research.

Evaluating the Chances of Survival in Cancer Patients

The global acute lymphoblastic leukaemia market is at an important juncture as several research lines are underway. The research laboratories engaged in cancer research have been steadfast in developing treatment lines for leukaemia. The chances of survival in individuals diagnosed with acute lymphoblastic leukaemia are lesser as compared to people suffering from other cancers. This is because acute leukaemia progressively spreads through the body and blood cells. This form of cancer is responsible for inducing the development of immature cells in the human body instead of mature cells. It is crucial to understand the action of acute lymphoblastic leukaemia in the human body to develop effective treatment lines. Several research studies provide information on the genesis of acute lymphoblastic leukaemia, but there has been limited success in development of treatment lines.

Information from the National Cancer Institute (NCI)

As research labs study the survival rates of people suffering from acute lymphoblastic leukaemia, the National Cancer Institute (NCI) is providing key statistics and information. NCI finds that the five-year survival rate of children in America suffering from acute lymphoblastic leukaemia is 85 percent. It means that 85% of children diagnosed with acute lymphoblastic leukaemia would live at least 5 years post their diagnosis with cancer. This is an important consideration for the healthcare industry that is evaluating the treatment lines for cancers. On account of the aforementioned trend, it is safe to say that the topic about leukaemia and other cancers has gained traction from several entities. The chances of surviving a cancer also depends on the stage at which the diagnosis is made. Stage-4 leukaemia is extremely difficult to manage, raising concerns across the medical industry.

Incidence of Leukaemia in Various Age Groups

On the basis of age group, the global acute lymphoblastic leukaemia can be segmented into infants and children, young adults, old adults, and geriatric population. Young adults, with their improved immunity, are more likely to survive through acute lymphoblastic leukaemia. Besides, research related to treatment and management of cancers in children has given a thrust to the growth of the global acute lymphoblastic leukaemia market. The medical industry is focusing on driving discussions around cancer care and awareness. Several new entities have shown interest in investing in the domain of leukaemia. Cancer-Care Foundations, fundraisers, and organizations have helped in spreading awareness about various types of cancers. All of the aforementioned trends have attracted increased revenues into the global acute lymphoblastic leukaemia market.

Key Research Initiatives and Treatment Lines

On the basis of cell type, the global acute lymphoblastic leukaemia market can be segmented into B-cell and T-cell. It is difficult to prioritise research for one cell type over the other. Therefore, the medical research sector pays equal attention to the analysis of both these cell types. Research initiatives of the medical and healthcare industries have made a huge difference to the way people perceive cancers. The sentiment that cancers are not curable has alleviated and faded out in recent times, giving a positive sign to vendors operating in the acute lymphoblastic leukaemia market. The steadily increasing success rate of surgeries and treatment lines for managing acute lymphoblastic leukaemia has given an impetus to market growth.

On the basis of treatment line, the global acute lymphoblastic leukaemia market can be segmented into radiation therapy, targeted therapy, chemotherapy, bone marrow therapy, and immunotherapy. Radiation therapy has proved to be useful for several patients, driving demand for this type of treatment. Most patients prefer radiation therapy over chemotherapy, creating new inlets for growth within the market. The pain and suffering associated with the use of chemotherapy has caused panic amongst the patients. Other treatment lines are also expected to gain momentum and popularity in the times to follow.

Acute Lymphoblastic Leukemia Market: Snapshot

Acute lymphoblastic leukemia, also known as ALL, is a type of cancer that affects lymphoid line of blood cells. It causes the development of large numbers of immature lymphocytes. Acute lymphoblastic leukemia is known to progress rapidly and can prove to be fatal within months or even weeks if it is not promptly treated. Hence, the short window period between diagnosis and beginning treatment for ALL drives the need for innovation of diagnostic tools and efficient treatment therapies in global acute lymphoblastic leukemia market. Symptoms for ALL may include fatigue, loss of appetite, fever, nose bleeds, enlarged lymph nodes, shortness of breath, pale skin color, easy bruising or bleeding, or bone pain. Acute lymphoblastic leukemia is known to quickly invade other organs in human body after its development in bone marrow. These may include liver, central nervous system, blood, and spleen. Rising awareness regarding acute lymphoblastic leukemia and increasing number of bone marrow biopsies are influencing the growing global acute lymphoblastic leukemia market.

Manufacturers and players in global acute lymphoblastic leukemia market are increasingly investing in research and development activities to develop new and advanced drugs. Rising number of clinical trials along with higher rate of new product approvals is anticipated to further the global acute lymphoblastic leukemia market in near future. However, adverse side effects of some of the drugs used in ALL treatment therapy and higher cost of these therapies can impede the growth in acute lymphoblastic leukemia market in coming years. Patent expiry of well-known and highly effective drugs also remain a problem for manufacturers in the industry. Some of the major players in global acute lymphoblastic leukemia market include Sanofi, Novartis AG, Erytech Pharma Inc., Amgen, Inc., Spectrum Pharmaceuticals, Inc., Pfizer, F. Hoffmann- La Roche Ltd., Celgene Corporation, and Bristol-Myers Squibb Company. Acute lymphoblastic leukemia is considered to be one of the most common kinds of cancer in pediatric population. Manufacturers and players in global acute lymphoblastic leukemia market are engaging in research and development activities to meet the rising demand for enhanced and cost efficient therapeutic drugs for the treatment of pediatric population suffering from ALL.

Global Acute Lymphoblastic Leukemia Market: Overview

This report analyzes the current and future scenario of the global acute lymphoblastic leukemia market. Increase in patient population with acute lymphoblastic leukemia, expansion of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be major drivers of the global market during the forecast period.

The global acute lymphoblastic leukemia market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment, type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global acute lymphoblastic leukemia market.

Global Acute Lymphoblastic Leukemia Market: Key Segments

In terms of type, the global acute lymphoblastic leukemia market has been classified into B-cell and T-cell. Based on treatment, the global acute lymphoblastic leukemia market has been segregated into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The segments have been analyzed based on available drug product used during the treatment of acute lymphoblastic leukemia, cost-effectiveness, and preference for industries. In terms of end-user, the global market has been divided into hospitals, clinics, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Acute Lymphoblastic Leukemia Market: Regional Outlook

In terms of region, the global acute lymphoblastic leukemia market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global acute lymphoblastic leukemia market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in the market report include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma Inc., Celgene Corporation, Amgen, Inc. Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc.

The global acute lymphoblastic leukemia market has been segmented as below:

Type

  • B-cell
  • T-cell

Treatment

  • Chemotherapy
  • Radiation Therapy
  • Bone Marrow Transplant
  • Targeted Therapy
  • Immunotherapy

End-user

  • Hospitals
  • Clinics
  • Others

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

1. Preface 
     1.1. Report Scope and Market Segmentation 
     1.2. Research Highlights

2. Assumptions and Research Methodology 
     2.1. Assumptions and Acronyms Used
     2.2. Research Methodology

3. Executive Summary

4. Market Overview
     4.1. Introduction
     4.2. Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026 
     4.3. Global Acute Lymphoblastic Leukemia Market Outlook
     4.4. Key Industry Developments

5. Market Dynamics
     5.1. Drivers and Restraints Snapshot Analysis
     5.2. Drivers
     5.3. Restraints
     5.4. Opportunities
     5.5. Key Trends

6. Global Acute Lymphoblastic Leukemia Market, by Type
     6.1. Introduction 
     6.2. Global Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     6.3. Global Acute Lymphoblastic Leukemia Market Value Forecast, by Type
     6.4. Global Acute Lymphoblastic Leukemia Market Analysis, by Type
            6.4.1. B-cell
            6.4.2. T-cell

7. Global Acute Lymphoblastic Leukemia Market, by Treatment
     7.1. Key Findings 
     7.2. Introduction 
     7.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment 
     7.4. Global Acute Lymphoblastic Leukemia Market Forecast, Treatment
     7.5. Global Acute Lymphoblastic Leukemia Market Analysis, by Treatment
            7.5.1. Chemotherapy
            7.5.2. Radiation Therapy
            7.5.3. Bone Marrow Transplant
            7.5.4. Targeted Therapy
            7.5.5. Immunotherapy
     7.6. Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment

8. Global Acute Lymphoblastic Leukemia Market, by End-user
     8.1. Key Findings 
     8.2. Introduction
     8.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user 
     8.4. Global Acute Lymphoblastic Leukemia Market Forecast, by End-user
     8.5. Global Acute Lymphoblastic Leukemia Market Analysis, by End-user
            8.5.1. Hospitals
            8.5.2. Clinics
            8.5.3. Others
     8.6. Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

9. Acute Lymphoblastic Leukemia Market Analysis, by Region
     9.1. Key Findings
     9.2. Global Market Scenario
     9.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region
     9.4. Global Acute Lymphoblastic Leukemia Market Forecast, by Region
            9.4.1. North America
            9.4.2. Europe
            9.4.3. Asia Pacific
            9.4.4. Latin America
            9.4.5. Middle East & Africa
     9.5. Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region

10. North America Acute Lymphoblastic Leukemia Market
     10.1. Key Findings
     10.2. North America Acute Lymphoblastic Leukemia Market Overview
     10.3. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
     10.4. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Country
            10.4.1. U.S.
            10.4.2. Canada
     10.5. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     10.6. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Type
            10.6.1. B-cell
            10.6.2. T-cell
     10.7. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
     10.8. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
            10.8.1. Chemotherapy
            10.8.2. Radiation Therapy
            10.8.3. Bone Marrow Transplant
            10.8.4. Targeted Therapy
            10.8.5. Immunotherapy
     10.9. North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
     10.10. North America Acute Lymphoblastic Leukemia Market Forecast, End-user
            10.10.1. Hospitals
            10.10.2. Clinics
            10.10.3. Others
     10.11. North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

11. Europe Acute Lymphoblastic Leukemia Market
     11.1. Key Findings
     11.2. Europe Acute Lymphoblastic Leukemia Market Overview
     11.3. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
     11.4. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
            11.4.1. Germany
            11.4.2. U.K.
            11.4.3. France
            11.4.4. Spain
            11.4.5. Italy
            11.4.6. Rest of Europe
     11.5. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     11.6. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Type
            11.6.1. B-cell
            11.6.2. T-cell
     11.7. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
     11.8. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
            11.8.1. Chemotherapy
            11.8.2. Radiation Therapy
            11.8.3. Bone Marrow Transplant
            11.8.4. Targeted Therapy
            11.8.5. Immunotherapy
     11.9. Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
     11.10. Europe Acute Lymphoblastic Leukemia Market Forecast, End-user
            11.10.1. Hospitals
            11.10.2. Clinics
            11.10.3. Others
     11.11. Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

12. Asia Pacific Acute Lymphoblastic Leukemia Market
     12.1. Key Findings
     12.2. Asia Pacific Acute Lymphoblastic Leukemia Market Overview
     12.3. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
     12.4. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
            12.4.1. China
            12.4.2. Japan
            12.4.3. India
            12.4.4. Australia & New Zealand
            12.4.5. Rest of Asia Pacific
     12.5. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     12.6. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Type
            12.6.1. B-cell
            12.6.2. T-cell
     12.7. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
     12.8. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
            12.8.1. Chemotherapy
            12.8.2. Radiation Therapy
            12.8.3. Bone Marrow Transplant
            12.8.4. Targeted Therapy
            12.8.5. Immunotherapy
     12.9. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
     12.10. Asia Pacific Acute Lymphoblastic Leukemia Market Forecast, End-user
            12.10.1. Hospitals
            12.10.2. Clinics
            12.10.3. Others
     12.11. Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

13. Latin America Acute Lymphoblastic Leukemia Market
     13.1. Key Findings
     13.2. Latin America Acute Lymphoblastic Leukemia Market Overview
     13.3. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
     13.4. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
            13.4.1. Brazil
            13.4.2. Mexico
            13.4.3. Rest of Latin America
     13.5. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     13.6. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Type
            13.6.1. B-cell
            13.6.2. T-cell
     13.7. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
     13.8. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
            13.8.1. Chemotherapy
            13.8.2. Radiation Therapy
            13.8.3. Bone Marrow Transplant
            13.8.4. Targeted Therapy
            13.8.5. Immunotherapy
     13.9. Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
     13.10. Latin America Acute Lymphoblastic Leukemia Market Forecast, End-user
            13.10.1. Hospitals
            13.10.2. Clinics
            13.10.3. Others
     13.11. Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

14. Middle East & Africa Acute Lymphoblastic Leukemia Market
     14.1. Key Findings
     14.2. Middle East & Africa Acute Lymphoblastic Leukemia Market Overview
     14.3. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
     14.4. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Country
            14.4.1. GCC Countries
            14.4.2. Israel
            14.4.3. South Africa
            14.4.4. Rest of Middle East & Africa
     14.5. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
     14.6. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Type
            14.6.1. B-cell
            14.6.2. T-cell
     14.7. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
     14.8. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
            14.8.1. Chemotherapy
            14.8.2. Radiation Therapy
            14.8.3. Bone Marrow Transplant
            14.8.4. Targeted Therapy
            14.8.5. Immunotherapy
     14.9. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
     14.10. Middle East & Africa Acute Lymphoblastic Leukemia Market Forecast, End-user
     14.11. Hospitals
     14.12. Clinics
     14.13. Others
     14.14. Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

15. Competition Landscape
     15.1. Acute Lymphoblastic Leukemia Market Share Analysis, by Company 
     15.2. Competition Matrix 
     15.3. Company Profile 
            15.3.1. Pfizer, Inc. 
                      15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.1.2. Financial Overview
                      15.3.1.3. Product Portfolio
                      15.3.1.4. SWOT Analysis
                      15.3.1.5. Strategic Overview
            15.3.2. Novartis AG 
                      15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.2.2. Financial Overview
                      15.3.2.3. Product Portfolio
                      15.3.2.4. SWOT Analysis
                      15.3.2.5. Strategic Overview
            15.3.3. F. Hoffmann-La Roche Ltd. 
                      15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.3.2. Financial Overview
                      15.3.3.3. Product Portfolio
                      15.3.3.4. SWOT Analysis
                      15.3.3.5. Strategic Overview
            15.3.4. Sanofi 
                      15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.4.2. Financial Overview
                      15.3.4.3. Product Portfolio
                      15.3.4.4. SWOT Analysis
                      15.3.4.5. Strategic Overview
            15.3.5. Erytech Pharma Inc. 
                      15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.5.2. Financial Overview
                      15.3.5.3. Product Portfolio
                      15.3.5.4. SWOT Analysis
                      15.3.5.5. Strategic Overview
            15.3.6. CELGENE CORPORATION 
                      15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.6.2. Financial Overview
                      15.3.6.3. Product Portfolio
                      15.3.6.4. SWOT Analysis
                      15.3.6.5. Strategic Overview
            15.3.7. Amgen, Inc.
                      15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.7.2. Financial Overview
                      15.3.7.3. Product Portfolio
                      15.3.7.4. SWOT Analysis
                      15.3.7.5. Strategic Overview
            15.3.8. Bristol-Myers Squibb Company 
                      15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.8.2. Financial Overview
                      15.3.8.3. Product Portfolio
                      15.3.8.4. SWOT Analysis
                      15.3.8.5. Strategic Overview
            15.3.9. Spectrum Pharmaceuticals, Inc. 
                      15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.3.9.2. Financial Overview
                      15.3.9.3. Product Portfolio
                      15.3.9.4. SWOT Analysis
                      15.3.9.5. Strategic Overview

List of Tables

Table 01: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 02: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016 – 2026
Table 03: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 04: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country,
Table 06: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 07: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 08: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 09: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region,
Table 10: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 11: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 12: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 13: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 15: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 16: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 17: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region,
Table 18: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 19: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 20: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 21: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 23: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 24: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user,

List of Figures

Figure 01: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type (2017)
Figure 03: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment (2017)
Figure 04: Global Acute Lymphoblastic Leukemia Market Value Share (%), by End-user (2017)
Figure 05: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Region (2017)
Figure 06: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type, 2018 and 2026
Figure 07: Global Acute Lymphoblastic Leukemia Market Attractiveness, by Type, 2018–2026
Figure 08: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by B-cell
Figure 09: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by T-cell
Figure 10: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2018-2026
Figure 11: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy
Figure 12: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Radiation Therapy, 2016–2026
Figure 13: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Bone Marrow Transplant
Figure 14: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy, 2016–2026
Figure 15: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2016–2026
Figure 16: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2018-2026
Figure 17: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 18: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospitals
Figure 19: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2016–2026
Figure 20: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 21: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
Figure 22: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region, 2018 and 2026
Figure 23: Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region, 2018-2026
Figure 24: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 25: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country, 2018 and 2026
Figure 26: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country, 2018–2026
Figure 27: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 28: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 29: North America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 30: North America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 31: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 32: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 33: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 34: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 35: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 36: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 37: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 38: Europe Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 39: Europe Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 40: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 41: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 42: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 43: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 44: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 45: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 46: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 47: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 48: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 49: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 50: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 51: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 52: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 53: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 54: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 55: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 56: Latin America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 57: Latin America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 58: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 59: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 60: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
Figure 61: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 62: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 63: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 64: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 65: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 66: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 67: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 68: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
Figure 69: Global Acute Lymphoblastic Leukemia Market Share, by Company, 2017
Figure 70: Pfizer, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 71: Pfizer, Inc.’s Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 72: Pfizer, Inc.’s Revenue Share (%), by Business Segment, 2017
Figure 73: Pfizer, Inc.’s Revenue Share (%), by Region, 2017
Figure 74: Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 75: Novartis AG’s Oncology Business Segment Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
Figure 76: Novartis AG’s Net Sales (%), by Business Segment, 2017
Figure 77: Novartis AG’s Net Sales (%), by Region, 2017
Figure 78: F. Hoffmann-La Roche Ltd.’s, Oncology Segment, Revenue (US$ Bn), 2015–2017
Figure 79: F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
Figure 80: F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment Revenue (%), by Specialty (2017)
Figure 81: F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment Revenue (%), by Region (2017)
Figure 82: Sanofi’s Revenue (US$ Bn), 2014?2017
Figure 83: Sanofi’s Regional Sales Breakdown (%), 2017
Figure 84: CELGENE CORPORATION Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 85: CELGENE CORPORATION Marketing & Sales and R&D Expenses (%), 2015–2017
Figure 86: CELGENE CORPORATION Breakdown of Net Sales (%), by Business Segment, 2017
Figure 87: CELGENE CORPORATION Breakdown of Net Sales (%), by Region, 2017
Figure 88: Amgen, Inc. Marketing & Sales and R&D Expenses (%), 2015–2017
Figure 89: Amgen, Inc. Breakdown of Net Sales (%), by Region, 2017
Figure 90: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 91: Bristol-Myers Squibb Company Revenue (US$ Bn), 2014-2017
Figure 92: Bristol-Myers Squibb Company R&D Expenditure (US$ Bn), 2015- 2017
Figure 93: Bristol-Myers Squibb Company Revenue, by Geography, 2017
Figure 94: Spectrum Pharmaceuticals, Inc. Revenue (US$ Mn), 2015- 2017
Figure 95: Spectrum Pharmaceuticals, Inc. R&D Expenditure (US$ Mn), 2014-2017

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Acute Lymphoblastic Leukemia Market